Highlights from Dr. Kalyanasundaram Subramanian's Presentation at T20 Bio Tonacea Conference 2024

Differentia's Kalyanasundaram Subramanian presented at T20 Bio Tonacea Conference 2024

The T20 Bio Tonacea Conference 2024 witnessed a landmark presentation by Dr. Kalyanasundaram Subramanian, CEO of Differentia and a Fellow of the Indian National Academy of Engineering. His keynote, titled "Applications of Quantitative Systems Pharmacology (QSP) in ADC New Drug Development," provided a comprehensive overview of how QSP is revolutionizing drug discovery and development.

Dr. Subramanian's Journey in Modeling

Dr. Subramanian's illustrious career began at Johns Hopkins University, where he contributed to brain tumor modeling. His subsequent roles included pioneering work at Entelos Inc., the first QSP company, and leading various modeling teams at Strand Life Sciences, Syngene International, and Applied Biomath. As the CEO of Differentia, he has driven advancements in QSP, PK/PD, PMX, Clinical Pharmacology, and Data Sciences, working on 45 projects in late discovery and early clinical stages.

The Role of Modeling in Drug Development

Modeling, as emphasized by Dr. Subramanian, enhances the efficiency of drug discovery and increases the probability of success. It allows for hypothesis testing and early identification of potential failures, thereby accelerating the development process. Key applications include:

Target Selection and Validation: Mechanistic models of disease pathways enable the identification and validation of therapy targets.
Lead Selection and Optimization: Disease models help determine optimal pharmacokinetic, pharmacodynamic, and ADME properties.
Therapeutic Window Characterization: Models characterize the balance between safety and efficacy for selected leads.
Model-Informed Drug Development (MIDD)
MIDD improves the understanding of disease mechanisms and drug actions, leading to:
First-in-Human Dose Selection: Accurate translation of preclinical findings to determine safe and efficacious doses.
Dose Escalation and Expansion: Establishing dose-response relationships to optimize dosing regimens.
Patient Segmentation: Identifying target patient groups and appropriate dosing strategies.

Regulatory bodies like the FDA and EMA encourage the use of MIDD due to its potential to reduce clinical trial lengths, increase success rates, and save substantial costs.

Quantitative Systems Pharmacology (QSP) Modeling

QSP models integrate disease networks and event cascades post-target engagement, providing a detailed understanding of drug mechanisms and disease progression. This approach offers:

Mechanism of Action Insights: Detailed descriptions of how drugs interact with their targets.
Biomarker Identification: Predictive biomarkers for drug efficacy.
Patient Stratification: Criteria for segmenting patient groups based on mechanistic differences.
Novel Target Identification: Discovering new

ADC Platform Model

Dr. Subramanian introduced an integrative ADC platform model calibrated with HER2 targeting ADCs like trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd). This platform aids in:

Clinical Predictions: Translating preclinical data to predict clinical outcomes, including dosing and toxicity.
Regulatory Support: Assisting in regulatory submissions and addressing queries from authorities.
Pipeline Applications: Supporting various stages of drug discovery and development, from target combination identification to dose justification and label recommendations.

Dr. Subramanian's presentation at the Tonacea Conference 2024 showcased the significant advancements in drug development made possible by QSP and MIDD. His insights into the modeling strategies and their practical applications in ADC development highlight a promising future for more efficient, accurate, and cost-effective drug discovery and development processes.

As the pharmaceutical industry continues to embrace these innovative approaches, the potential for bringing safer and more effective drugs to market increases, ultimately benefiting patients worldwide.